Skip to main content

Table 1 Clinical data of mTLE and Control patients

From: Protein expression profiling of inflammatory mediators in human temporal lobe epilepsy reveals co-activation of multiple chemokines and cytokines

Patient group Age Sex Pathology/COD Tissue used Seizure frequency iEcOG spikes Anti-epileptic drugs Engel score (1 yr)
1) Control 73 F subdural hematoma HC NA NA NA NA
2) Control 58 M unknown. ALS patient HC & CX NA NA NA NA
3) Control 62 M unknown, non-demented control HC & CX NA NA NA NA
4) Control 94 F CVA HC & CX NA NA NA NA
5) Control 71 M pancreas carcinoma HC & CX NA NA NA NA
6) Control 64 F respiratory failure HC & CX NA NA NA NA
7) Control 70 M sepsis with broncopneumonia HC NA NA NA NA
8) Control 50 F metastasized broncocarcinoma HC & CX NA NA NA NA
9) Control 48 M DMT I induced organ failure HC NA NA NA NA
10) Control 74 M pulmonary carcinoma HC & CX NA NA NA NA
11) Control 62 F renal carcinoma (euthanasia) CX NA NA NA NA
12) Control 93 F heart failure CX NA NA NA NA
13) Control 92 F cachexia/dehydration CX NA NA NA NA
14) non-HS 45 M W0, FCD type1 to 2A in cortex HC 6 CX LTG, PHT 1A
15) non-HS 46 F W0, MCD type 1 in cortex HC 12 CX CBZ, VPA 1A
16) non-HS 46 M W0, epilepsy after head trauma HC 90 HC & CX CBZ, VPA, TPR 1B
17) non-HS 42 F W0, DNT WHO grade I HC & CX 1 CX CBZ, LTG, LEV 1A
18) non-HS 34 F W0, cortical cavernoma HC 1.5 HC & CX CBZ 1A
19) non-HS 40 F W0, MCD type 1 in cortex HC 8 ( C ) HC & CX LEV, LTG, CBZ 1A
20) non-HS 43 F W0, therapy resistant epilepsy HC & CX 40 ( C ) HC & CX PHT, LTG 1A
21) non-HS 47 M W0, therapy resistant epilepsy HC 30 HC CBZ, VPA, LTG, LEV 3A
22) non-HS 28 M W0, MCD type 1 in cortex HC 60 HC & CX CBZ, TPR. 1A
23) non-HS 54 M W0, ganglioglioma WHO grade I HC & CX 1.5 HC & CX OXC, LTG, CLO 1A
24) non-HS 30 M W0, therapy resistant epilepsy CX 8 HC & CX OXC, LEV, CLO 1A
25) non-HS 37 F W0, therapy resistant epilepsy CX 1 not measured LTG, CLO 1A
26) non-HS 61 M W0, therapy resistant epilepsy CX 5.5 HC & CX PHT, CBZ 2A
27) non-HS 19 M W0, ganglioglioma WHO grade II CX 1 None VPA, LEV 1A
28) non-HS 27 F W0, therapy resistant epilepsy CX 16 HC & CX LEV 1A
29) non-HS 46 M W0, cavernoma in uncus CX 60 HC CBZ, VPA, OXC, LEV, LTG 1A
30) non-HS 44 M W0, therapy resistant epilepsy CX 18 HC & CX TPR, OXC 1A
31) HS 41 M MTS W4 HC & CX 12 not measured PHT, CLO, CBZ, LTG 1A
32) HS 44 F MTS W2 HC 8 ( C ) not measured CBZ, OXC, CLO 1A
33) HS 41 M MTS W4 HC 3 not measured CBZ 1A
34) HS 52 F MTS W4 HC & CX 10 not measured CBZ, CLO, DZP 2D
35) HS 50 M MTS W4 HC 18 not measured CBZ, GBP 2A
36) HS 36 F MTS W4 HC & CX 2 not measured OXC, LZP no info
37) HS 42 M MTS W4 HC & CX 2 not measured LEV, LTG 2A
38) HS 36 M MTS W4 HC & CX 10 HC & CX OXC, PGB 1B
39) HS 49 F MTS W4 HC 8 ( C ) not measured OXC, CLO 1A
40) HS 42 F MTS W4 HC 4.5 not measured LEV, LTG, PBT 1A
41) HS 36 M MTS W4 CX 5 not measured PGB, LTG 1A
42) HS 34 F MTS W4 CX 10 ( C ) HC & CX LTG, CBZ, VPA,CLO 2A
43) HS 49 M MTS W3 CX 1 None LTG, CBZ, CLO 1A
44) HS 45 M MTS W4 CX 0.5 not measured GBP, LTG 1A
45) HS 48 M MTS W4 CX 3.5 not measured CBZ, LTG, VPA 1A
  1. Hippocampal (HC) and neocortical (CX) homogenates were prepared from tissue of the listed patients as indicated in column 5. All epilepsy patients suffered therapy resistant epilepsy, any additional pathologies are listed in column 4. Seizure frequencies are listed as an average of monthly activity, patients who suffered clustered attacks are marked (C). iEcOG spikes indicate epileptic spike activity detected by iEcOG at surgery. Engel scores were recorded 1 year after surgery [35]. Abbreviations: ALS amyotrophic lateral sclerosis, CBZ Carbamazepine, COD cause of death, CLO Clobazam, CVA cerebrovascular accident, CX temporal neocortex, DMT I diabetes mellitus type I, DNT Dysembryonic neuroepithelial tumor, DZP diazepam, FCD focal cortical dysplasia, GBP Gabapentin, HC hippocampus, HS hippocampal sclerosis, iEcOG intraoperative electrocorticography, LEV Levetiracetam, LTG Lamotrigine, LZP Lorazepam, MCD malformation of cortical development, MTS mesial temporal sclerosis, NA not applicable, OXC Oxcarbazepine, PBT Phenobarbital, PGB Pregabaline, PHT Phenytoin, PMD post mortem delay, RIN RNA integrity number, TPR Topiramate; VPA Valproinic acid, W0 till 4 Wyler score, WHO grade world health organization grading scale of malignancy.